CD4 and autoimmune disease: In fact, in consistent with the findings in murine primary CD4+ T cells, TRAIL profoundly suppressed T cell proliferation and interleukin-2 (IL-2) production in human CD4+ T cells from patient with autoimmune diseases (Supplementary Fig. S3).